 |
|
Low-Dosage Asparaginase Treatment of Childhood Acute Lymphocytic Leukemia
Charles B. Pratt, MD;
Sun-I Choi, MD;
Charlene P. Holton, MD
Am J Dis Child. 1971;121(5):406-409.
Abstract
Asparaginase was administered to children with acute lymphocytic leukemia in dosages less than those generally used. The objectives were to determine whether toxicity of the enzyme could be reduced without loss of efficacy, and to compare weekly with twice weekly administration. In five of 11 children who received 5,000 international units (IU)/sq m twice weekly for four doses and four of ten who received 10,000 IU/sq m once weekly for two doses, examination of bone marrow showed complete remission. Although the usual asparaginase-induced toxic reactions occurred, there were no deaths due to toxic reaction and no clinical signs of pancreatic dysfunction. Toxic reactions were comparable in the once weekly and twice weekly groups. Toxicity can be decreased without loss of efficacy by using these reduced dosage schedules.
Author Affiliations
Memphis; Denver
From St. Jude Children's Research Hospital, University of Tennessee Medical Units (Drs. Pratt and Choi), Memphis; and the Oncology Center, Children's Hospital, Denver (Dr. Holton).
Footnotes
Received for publication Sept 1, 1970.
Read before the 61st annual meeting of the American Association for Cancer Research, Philadelphia, April 11, 1970.
Reprint requests to St. Jude Children's Research Hospital, 332 N Lauderdale, PO Box 318, Memphis 38101 (Dr. Pratt).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia
Woo et al.
JCO 2000;18:1525-1532.
ABSTRACT
| FULL TEXT
Anaphylactic Reactions to Chemotherapeutic Agents
Hammond
Journal of Pediatric Oncology Nursing 1988;5:16-19.
|
